INCY vs NVS
INCY: A biopharmaceutical company pioneering targeted therapies for blood cancers and inflammatory diseases, with flagship JAK inhibitor JAKAFI generating substantial cash flow. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | INCY | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $115.79 | $153.08 | |
| Market cap as of 2026-07-23 | $23.3B | $229.2B | |
| P/E as of 2026-07-23 | 16.29 | 22.11 | INCY lower |
| PEG as of 2026-07-23 | 1.00 | 3.66 | INCY lower |
| Net margin as of 2026-07-23 | +26.7% | +22.5% | INCY higher |
| Gross margin as of 2026-07-23 | +93.0% | +75.0% | INCY higher |
| Operating margin as of 2026-07-23 | +30.1% | +29.9% | INCY higher |
| ROE as of 2026-07-23 | +29.2% | +29.9% | NVS higher |
| ROA as of 2026-07-23 | +21.6% | +11.1% | INCY higher |
| Debt / equity as of 2026-07-23 | 0.01 | 1.18 | INCY lower |
| Revenue growth (YoY) as of 2026-07-23 | +21.5% | +3.3% | INCY higher |
| Revenue CAGR (3y) SEC XBRL | +14.8% | n/a | |
| Dividend yield as of 2026-07-23 | n/a | +3.0% | |
| Beta as of 2026-07-23 | 0.77 | 1.17 | |
| 1-year return as of 2026-07-22 close | +74.2% | +35.8% | INCY higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.